6 active not recruiting. 6 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Active not recruiting 6 |
| Phase 2 | 3 | Active not recruiting 3 |
Follow Glaucoma: new trials by email Literature Review of Glaucoma trials Research Report on Glaucoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluate Efficacy, Safety, Tolerability and Biodegradation of PA5346 Ocular Implant in Patients With Open-Angle Glaucoma or Ocular Hypertension PA5436 Ocular Implant, 115mcg - Open Angle Glaucoma (OAG), Ocular Hypertension (OH) | Phase 1 | Active not recruiting | PolyActiva Pty Ltd | 12 | 2025-06-10 | 2026-07-07 |
| Pilot Study on a New Self Adjustable Glaucoma Drainage Device eyeValve - Glaucoma | Phase 1 | Active not recruiting | Rheon Medical SA | 10 | 2025-06-01 | 2026-03-18 |
| Evaluation of the Bimatoprost Implant System Used in Combination With the SpyGlass Intraocular Lens Compared to Timolol Ophthalmic Solution Bimatoprost Implant System (High Dose), Bimatoprost Implant System (Low Dose), Timolol Maleate Ophthalmic Solution, 0.5% - Cataract, Glaucoma | Phase 1 / Phase 2 | Active not recruiting | SpyGlass Pharma, Inc. | 201 | 2023-10-13 | 2025-08-22 |
| Safety Assessment of T4090 Eye Drops in Ocular Hypertensive or Glaucomatous Patients. Kinezodianone R hydrochloride, Placebo - Glaucoma, Ocular Hypertension | Phase 1 / Phase 2 | Active not recruiting | Laboratoires Thea | 120 | 2022-07-05 | 2024-02-07 |
| KDR2-2 Suspension Eyedrop in the Treatment of Neovascular Glaucoma (KDR-NVG) Trial 4mg/ml KDR2-2 suspension eyedrop, 16mg/ml KDR2-2 suspension eyedrop - Neovascular Glaucoma, Neovascularization | Phase 1 | Active not recruiting | Sun Yat-sen University | 40 | 2021-04-19 | 2024-12-11 |
| AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension AGN-193408 SR, Lumigan, Sham Administration - Open-angle Glaucoma, Ocular Hypertension | Phase 1 / Phase 2 | Active not recruiting | AbbVie | 100 | 2020-11-16 | 2026-05-22 |
Ocular Hypertension (4) · Glaucoma, Open-Angle (2) · Cataract (1) · Glaucoma, Neovascular (1) · Neovascularization, Pathologic (1)
Eye Diseases (6) · Ocular Hypertension (2) · Lens Diseases (1) · Metaplasia (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1)
Bimatoprost (1)
AbbVie (1) · Laboratoires Thea (1) · PolyActiva Pty Ltd (1) · Rheon Medical SA (1) · SpyGlass Pharma, Inc. (1) · Sun Yat-sen University (1)
United States (3) · Australia (1) · China (1) · Japan (1) · Senegal (1)
Chris Hafner (1) · Xiulan Zhang, MD, PhD (1)